Objective scoring of hidradenitis suppurativa reflecting the role of tobacco smoking and obesity

British Journal of Dermatology

Volumn 161, Issue 4, 2009, Pages 831-839

  Sartorius, K ^a   Emtestam, L ^a   Jemec, G B E ^a   Lapins, J ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Body mass index; Dermatology Life Quality Index; Hidradenitis suppurativa; Scoring; Severity; Smoking

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; BODY MASS; CIGARETTE SMOKING; CONTROLLED STUDY; DERMATOLOGY LIFE QUALITY INDEX; DISEASE SEVERITY; FEMALE; HIDRADENITIS SUPPURITIVA SCORE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; OBESITY; PRIORITY JOURNAL; SCORING SYSTEM; SMOKING HABIT; SUPPURATIVE HIDRADENITIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FEMALE; HIDRADENITIS SUPPURATIVA; HUMANS; MALE; MIDDLE AGED; OBESITY; QUALITY OF LIFE; QUESTIONNAIRES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SMOKING; SWEDEN; YOUNG ADULT;

EID: 70349349164     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2009.09198.x     Document Type: Article

References (25)

1. Jemec GB, Heidenheim M, Nielsen NH. Hidradenitis suppurativa - characteristics and consequences. Clin Exp Dermatol 1996 21 : 419 423.
2. Jemec GB. Hidradenitis suppurativa. J Cutan Med Surg 2003 7 : 47 56.
3. Barth JH, Layton AM, Cunliffe WJ. Endocrine factors in pre- and postmenopausal women with hidradenitis suppurativa. Br J Dermatol 1996 134 : 1057 1059.
4. Konig A, Lehmann C, Rompel R et al. Cigarette smoking as a triggering factor of hidradenitis suppurativa. Dermatology 1999 198 : 261 264.
5. Revuz JE, Canoui-Poitrine F, Wolkenstein P et al. Prevalence and factors associated with hidradenitis suppurativa: results from two case-control studies. J Am Acad Dermatol 2008 59 : 596 601.
6. Jansen I, Altmeyer P, Plewig G. Acne inversa (alias hidradenitis suppurativa). J Eur Acad Dermatol Venereol 2001 15 : 532 540.
7. Lapins J, Sartorius K, Emtestam L. Scanner-assisted carbon dioxide laser surgery: a retrospective follow-up study of patients with hidradenitis suppurativa. J Am Acad Dermatol 2002 47 : 280 285.
8. Mendonca CO, Griffiths CE. Clindamycin and rifampicin combination therapy for hidradenitis suppurativa. Br J Dermatol 2006 154 : 977 978.
9. Cusack C, Buckley C. Etanercept: effective in the management of hidradenitis suppurativa. Br J Dermatol 2006 154 : 726 729.
10. Giamarellos-Bourboulis EJ, Antonopoulou A, Petropoulou C et al. Altered innate and adaptive immune responses in patients with hidradenitis suppurativa. Br J Dermatol 2007 156 : 51 6.
11. Gupta AK, Skinner AR. A review of the use of infliximab to manage cutaneous dermatoses. J Cutan Med Surg 2004 8 : 77 89.
12. Roussomoustakaki M, Dimoulios P, Chatzicostas C et al. Hidradenitis suppurativa associated with Crohn's disease and spondyloarthropathy: response to anti-TNF therapy. J Gastroenterol 2003 38 : 1000 1004.
13. Sullivan TP, Welsh E, Kerdel FA et al. Infliximab for hidradenitis suppurativa. Br J Dermatol 2003 149 : 1046 1049.
14. Hurley HJ. Axillary hyperhidrosis, apocrine bromhidrosis, hidradenitis suppurativa and familial benign pemphigus. Surgical approach. In : Dermatologic Surgery. Principles and Practice (Roenigk RK, Roenigk HH Jr., eds 2nd edn. New York : Marcel Dekker, 1996 623 645.
15. Sartorius K, Lapins J, Emtestam L et al. Suggestions for uniform outcome variables when reporting treatment effects in hidradenitis suppurativa. Br J Dermatol 2003 149 : 211 213.
16. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use. Clin Exp Dermatol 1994 19 : 210 216.
17. Hongbo Y, Thomas CL, Harrison MA et al. Translating the science of quality of life into practice: what do Dermatology Life Quality Index scores mean? J Invest Dermatol 2005 125 : 659 664.
18. von der Werth JM, Jemec GB. Morbidity in patients with hidradenitis suppurativa. Br J Dermatol 2001 144 : 809 813.
19. Wolkenstein P, Loundou A, Barrau K et al. Quality of life impairment in hidradenitis suppurativa: a study of 61 cases. J Am Acad Dermatol 2007 56 : 621 623.
20. Jemec GB, Wulf HC. Patient-physician consensus on quality of life in dermatology. Clin Exp Dermatol 1996 21 : 177 179.
21. Holm EA, Wulf HC, Stegmann H et al. Life quality assessment among patients with atopic eczema. Br J Dermatol 2006 154 : 719 725.
22. Fardet L, Dupuy A, Kerob D et al. Infliximab for severe hidradenitis suppurativa: transient clinical efficacy in 7 consecutive patients. J Am Acad Dermatol 2007 56 : 624 628.
23. Mekkes JR, Bos JD. Long-term efficacy of a single course of infliximab in hidradenitis suppurativa. Br J Dermatol 2008 158 : 370 374.
24. Giamarellos-Bourboulis EJ, Pelekanou E, Antonopoulou A et al. An open-label phase II study of the safety and efficacy of etanercept for the therapy of hidradenitis suppurativa. Br J Dermatol 2008 158 : 567 572.
25. Brunasso AM, Delfino C, Massone C. Hidradenitis suppurativa: are tumour necrosis factor-α blockers the ultimate alternative? Br J Dermatol 2008 159 : 761 763.